Présentation de l'entreprise
Annovis Bio, Inc. operates as a clinical stage drug platform company dedicated to the development of therapeutic agents targeting neurodegenerative conditions within the United States market. The entity functions within the healthcare sector, specifically the biotechnology industry, where its primary focus is on advancing pipeline candidates for complex neurological disorders such as Alzheimer's disease and Parkinson's disease. The company maintains a market capitalization of $65.22M and employs a workforce of 7 individuals, indicating a highly specialized and lean organizational structure typical of early-stage development firms. These valuation and operational metrics suggest that Annovis Bio is a micro-cap entity with limited current revenue streams, relying heavily on the successful progression of its lead product candidate, Buntanetap, to generate future economic value. The absence of reported annual revenue in the available data underscores the company's current position in the clinical development phase, where capital expenditure is directed toward research rather than commercial sales.
Santé financière
Annovis Bio reports a net income of $-28,854,196 over the trailing twelve-month period, while revenue and EBITDA figures are not available in the current dataset, highlighting a significant gap between operational output and profitability driven by substantial R&D and administrative expenditures. The company generated negative free cash flow amounting to $-15,183,042, which reflects a capital-intensive business model where cash outflows for research activities exceed the minimal cash inflows from operations. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for biotechnology firms in clinical stages that have not yet achieved commercial product launch or significant sales volume. Despite the lack of profitability, the company holds $19.53M in cash against $0 in debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt obligations. This balance sheet composition indicates a conservative financial stance regarding leverage, as the firm carries no interest-bearing liabilities to service. The current ratio stands at 5.80, demonstrating robust short-term liquidity where current assets significantly exceed current liabilities, providing ample buffer for ongoing research operations. Return on Equity is reported at -220.6% and Return on Assets at -106.0%, metrics that reveal the substantial dilution of shareholder value and asset efficiency typical of companies burning through capital to reach clinical milestones.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is not applicable due to the lack of net income, whereas the forward P/E ratio is listed at -2.13, a negative figure that implies the market is pricing in future earnings based on a valuation framework that does not yet reflect current profitability. The price-to-book ratio is 3.71, suggesting that the market assigns a premium to the company's intangible assets, such as its clinical-stage drug pipeline and intellectual property, relative to its book value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both not applicable, indicating that traditional sales-based or earnings-based multiples are not currently relevant for assessing the company's value in its pre-revenue stage. The stock has traded with a 52-week high of $5.50 and a 52-week low of $1.11, meaning the current valuation fluctuates within a wide historical range that reflects the high volatility inherent in small-cap biotechnology equities. The beta value of 1.36 indicates that the stock price is expected to exhibit higher volatility than the broader market, moving 36% more aggressively in response to market shifts.
Growth & Income
Revenue growth and earnings growth rates over the year-over-year period are not available in the current data, preventing a direct comparison of the speed at which earnings are growing relative to revenue expansion. As the company does not pay a dividend, the dividend yield and payout ratio are both not applicable, confirming that the firm reinvests all available resources and generates no income distributions for shareholders. The absence of a dividend policy aligns with the company's strategic necessity to retain capital for funding clinical trials and operational expenses rather than distributing cash to investors. Consequently, the overall growth and income profile of Annovis Bio is defined entirely by its potential to deliver future commercial value through the approval and sale of its neurodegenerative disease treatments, rather than current financial returns or income generation.